Enkai Cell Technology key facts
- Researcher of immune cell drugs designed for tumour patients.
- It has raised $28.9M; the latest was Early Stage VC ($13.9M) in Jul 2025.
- Notable investors include The Chinese Academy of Sciences Venture Capital Management, Yijin Capital, 3Sbio, Beijing FOF Capital, Chengyi Capital (Nanjing) — 11 tracked in total.
- Status: Privately Held (backing).
Who backs Enkai Cell Technology
11+- ·The complete investor list: 11 names
- ·Watch Enkai Cell Technology: the Monday email on marks, rounds and moves
Enkai Cell Technology funding rounds
No funding rounds for Enkai Cell Technology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Enkai Cell Technology investors
11 investors are on record for Enkai Cell Technology, including The Chinese Academy of Sciences Venture Capital Management, Yijin Capital, 3Sbio and Beijing FOF Capital.
About Enkai Cell Technology
Researcher of immune cell drugs designed for tumour patients. The company focuses on applying synthetic immunology technology to NK (Natural Killer) cells to artificially create various NK cells that meet different clinical needs, enabling tumour patients to get efficient treatment with fewer side effects.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2020
- Employees
- 60
- Website
- nk-celltech.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Enkai Cell Technology doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.